BPI and infectious disease: Recombinant N-terminal fragments of BPI (including rBPI23 and rBPI21 [opebacan, NEUPREX®]) possessing the LPS-binding and LPS-neutralizing activity of native BPI were developed by XOMA (US) LLC (Berkeley, CA) as anti-infective agents for use in sepsis and other infectious disease indications.